Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. Summary
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
04/16/2021 04/19/2021 04/20/2021 04/21/2021 04/22/2021 Date
1.63(c) 1.62(c) 1.59(c) 1.615(c) 1.59 Last
43 022 32 747 25 459 43 259 7 173 Volume
+1.56% -0.61% -1.85% +1.57% -1.55% Change
More quotes
Financials
Sales 2021 3,90 M 4,26 M 4,26 M
Net income 2021 -15,7 M -17,1 M -17,1 M
Net cash position 2021 11,0 M 12,0 M 12,0 M
P/E ratio 2021 -3,47x
Yield 2021 -
Sales 2022 1,28 M 1,39 M 1,39 M
Net income 2022 -25,8 M -28,2 M -28,2 M
Net Debt 2022 22,9 M 25,0 M 25,0 M
P/E ratio 2022 -2,26x
Yield 2022 -
Capitalization 54,9 M 59,9 M 60,0 M
EV / Sales 2021 11,3x
EV / Sales 2022 61,0x
Nbr of Employees 27
Free-Float 72,6%
More Financials
Company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced... 
Read more
More about the company
Notations Surperformance© of Addex Therapeutics Ltd
Trading Rating : Investor Rating :
More Ratings
All news about ADDEX THERAPEUTICS LTD
04/21ADDEX THERAPEUTICS  : HC Wainwright Initiates Addex Therapeutics at Buy Rating W..
MT
04/13PRESS RELEASE : Addex to Present at the 20th Annual Needham Virtual Healthcare C..
DJ
04/13Addex to Present at the 20th Annual Needham Virtual Healthcare Conference
GL
04/08ADDEX THERAPEUTICS  : Files Registration Statement for Equity Offering of Up to ..
MT
04/08PRESS RELEASE : Addex Files Registration Statement on Form F-3 with the US Secur..
DJ
04/08Addex Files Registration Statement on Form F-3 with the US Securities and Exc..
GL
04/08ADDEX THERAPEUTICS  : Eyes $150 Million Share Issue
MT
03/11PRESS RELEASE  : Addex Reports Full Year 2020 -2-
DJ
03/11PRESS RELEASE : Addex Reports Full Year 2020 Financial Results and Provides Corp..
DJ
03/11Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
GL
03/09PRESS RELEASE : Addex Therapeutics to Release Full-Year 2020 Financial Results a..
DJ
03/09ADDEX THERAPEUTICS  : to Release Full-Year 2020 Financial Results and Host Confe..
AQ
03/04PRESS RELEASE : Addex to Present at the H.C. Wainwright Global Life Sciences Con..
DJ
03/04Addex to Present at the H.C. Wainwright Global Life Sciences Conference
GL
02/24ADDEX THERAPEUTICS  : Enamine Extend Collaboration With Prominent Swiss Biotech
BU
More news
News in other languages on ADDEX THERAPEUTICS LTD
04/08Principales informations avant-Bourse
04/08Addex Therapeutics veut émettre plus facilement des actions américaines
04/07Addex will Aktien von bis zu 150 Mio Dollar ausgeben
04/07Addex veut émettre pour jusqu'à 150 millions de dollars d'actions
03/11Addex wegen Covid-19-Pandemie mit tieferen Forschungsausgaben 2020
More news
Analyst Recommendations on ADDEX THERAPEUTICS LTD
More recommendations
Chart ADDEX THERAPEUTICS LTD
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1,08 CHF
Last Close Price 1,62 CHF
Spread / Highest target -33,1%
Spread / Average Target -33,1%
Spread / Lowest Target -33,1%
EPS Revisions
Managers and Directors
NameTitle
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capitalization (M$)
ADDEX THERAPEUTICS LTD-18.84%60
MODERNA, INC.62.25%67 889
LONZA GROUP AG-2.00%45 162
IQVIA HOLDINGS INC.22.23%41 636
CELLTRION, INC.-19.08%35 463
SEAGEN INC.-15.79%26 741
Categories
Free services
Mobile App
SOLUTIONS
About
Stock Market Quotes Interactive brokers The best of tweets Stock Market News Börse: Aktien, Kurse und Nachrichten
Copyright © 2021 Surperformance. All rights reserved. Stock quotes are provided by Factset, Morningstar and S&P Capital IQ